GLYC News and Press, GlycoMimetics Inc. From 04/26/21

GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report first quarter financial results on Monday, May 3, 2021, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-...

Study demonstrates GMI-1757’s impact on immune cell infiltration and improvement of anti-PD-L1 therapeutic activity GlycoMimetics, Inc. (Nasdaq: GLYC) today announces that an abstract presenting the results of a recent preclinical study on the therapeutic effects of G...

- Preclinical research included in poster supports clinical findings and demonstrates enhanced immune response in metastatic breast carcinoma model GlycoMimetics, Inc. (Nasdaq: GLYC) today announces that a Phase 1b trial of GMI-1359, being conducted at Duke University Cancer...

Gainers: [[GLYC]] +3.5%. [[CBAY]] +2.6%. [[KPTI]] +2.6%. [[GMAB]] +2.5%. [[SYRS]] +2.4%.Losers: [[VECT]] -8.1%. [[TCRR]] -2.4%. [[JFIN]] -2.3%. [[CENX]] -2.2%. [[GURE]] -1.8%. For further details see: KPTI, CENX, GMAB and TCRR among after-hours movers

Innovation, R&D and an aging population are long-term secular trends that will provide a tailwind to the biotechnology sector. The Insurgent AI Deep Innovation Model uses Deep Learning and secular tailwinds to generate alpha. Evaluating investment strategies is challenging, es...

- Evidence of biologic activity of GMI-1359 observed in Phase 1b clinical trial interim analysis - Preclinical data highlight anti-tumor activity in pancreatic cancer model with GMI-1757, a novel galectin-3 antagonist GlycoMimetics, Inc. (Nasdaq: GLYC) today announces ...

The Asia Partners series of funds invests primarily in China and India, from venture capital through growth stage for biotech, pharma, medical device, diagnostic and healthcare companies. WuXi AppTec, a China-global CRO/CMO, paid $135 million to acquire Oxgene, a UK CDMO that develops...

GlycoMimetics (Nasdaq: GLYC) today announced that Apollomics has dosed the first patient in China in a Phase 1 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML). In February of this year, Apollomics ini...

Image source: The Motley Fool. GlycoMimetics Inc (NASDAQ: GLYC) Q4 2020 Earnings Call Mar 2, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: GlycoMimetics Inc (GLYC) Q4 2020 Earnings Call Transcript

GlycoMimetics, Inc. (GLYC) Q4 2020 Earnings Conference Call March 2, 2021 8:30 AM ET Company Participants Shari Annes - Investor Relations Rachel King - Chief Executive Officer Brian Hahn - Chief Financial Officer Eric Feldman - Chief Medical Officer (Incoming) Conference Call Participants Ze...